Last reviewed 2026-04-22 · How we verify

Diuretic Increase (DI)

Medtronic BRC · FDA-approved active Small molecule

Diuretic Increase (DI) is a Small molecule drug developed by Medtronic BRC. It is currently FDA-approved for Heart failure with fluid overload (presumed, based on diuretic enhancement indication).

Diuretic Increase (DI) is a device-based therapy from Medtronic that enhances diuretic efficacy, likely through optimized drug delivery or physiological modulation to increase urine output.

Diuretic Increase (DI) is a device-based therapy from Medtronic that enhances diuretic efficacy, likely through optimized drug delivery or physiological modulation to increase urine output. Used for Heart failure with fluid overload (presumed, based on diuretic enhancement indication).

At a glance

Generic name	Diuretic Increase (DI)
Sponsor	Medtronic BRC
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

As a marketed Medtronic product, DI appears to be a therapeutic device or drug-device combination designed to augment the effects of diuretic medications. The exact mechanism is not publicly detailed in standard pharmaceutical databases, but it likely involves either improved bioavailability of diuretics, targeted delivery to renal sites of action, or neuromodulation to enhance natriuresis and fluid removal.

Approved indications

Heart failure with fluid overload (presumed, based on diuretic enhancement indication)

Common side effects

No common side effects on file.

Key clinical trials

LINQ for impEdance meAsuremeNt While Off From HF Medication Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Diuretic Increase (DI) CI brief — competitive landscape report
Diuretic Increase (DI) updates RSS · CI watch RSS
Medtronic BRC portfolio CI

Frequently asked questions about Diuretic Increase (DI)

What is Diuretic Increase (DI)?

Diuretic Increase (DI) is a Small molecule drug developed by Medtronic BRC, indicated for Heart failure with fluid overload (presumed, based on diuretic enhancement indication).

How does Diuretic Increase (DI) work?

Diuretic Increase (DI) is a device-based therapy from Medtronic that enhances diuretic efficacy, likely through optimized drug delivery or physiological modulation to increase urine output.

What is Diuretic Increase (DI) used for?

Diuretic Increase (DI) is indicated for Heart failure with fluid overload (presumed, based on diuretic enhancement indication).

Who makes Diuretic Increase (DI)?

Diuretic Increase (DI) is developed and marketed by Medtronic BRC (see full Medtronic BRC pipeline at /company/medtronic-brc).

What development phase is Diuretic Increase (DI) in?

Diuretic Increase (DI) is FDA-approved (marketed).

Manufacturer: Medtronic BRC — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Heart failure with fluid overload (presumed, based on diuretic enhancement indication)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing